LBP Data shows Potential for Clinical Development

Biotherapeutics company 4D pharma (Leeds) has announced progress on its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518, an ongoing Phase I/II clinical trial in combination with immune checkpoint inhibitor (ICI) Keytruda(R) (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with advanced malignancies who have previously progressed on ICI therapy.

“4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. This clinical and development progress has been achieved in spite of the headwinds of COVID-19,” said Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma.  “As 4D pharma extends its leading position in this exciting and rapidly maturing field, we see the next 12 months as being instrumental for the space. We look forward to generating more clinical data from our ongoing studies of MRx0518 in multiple different tumour types and treatment settings. This will support 4D pharma’s continued productive engagement with regulatory authorities to develop the clinical strategy to bring this novel therapeutic to patients suffering from a range of cancers.”

Founded in February 2014, 4D pharma develops Live Biotherapeutics, an emerging class of drugs containing a live organism defined by the FDA as biological products that contain a live organism. It has developed a proprietary platform, MicroRx(R),that rationally identifies Live Biotherapeutics based on an understanding of function and mechanism.

Further information online